<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630019</url>
  </required_header>
  <id_info>
    <org_study_id>VPH0107</org_study_id>
    <nct_id>NCT00630019</nct_id>
  </id_info>
  <brief_title>Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vistakon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin
      ophthalmic solution or an active comparator in subjects undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of levofloxacin and active control in the aqueous humor</measure>
    <time_frame>Time of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5% levofloxacin ophthalmic solution</intervention_name>
    <description>Topical application</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% moxifloxacin hydrochloride ophthalmic solution</intervention_name>
    <description>Topical application</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of instilling eye drop

          -  Scheduled for cataract surgery with intraocular lens (IOL) implantation

          -  Be medically cleared for surgery

          -  Women must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or,
             if sexually active, be practicing an effective method of birth control before entry,
             and must agree to continue to use the same method of contraception throughout the
             study

          -  Women of childbearing potential must have a negative urine pregnancy test at
             screening.

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.

          -  Subjects (or his/her legally acceptable representative) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study.

        Exclusion Criteria:

          -  Known allergy or other contraindication to the test article(s) or their components.

          -  Presence of any abnormality or significant illness in the eye that in the
             investigator's opinion could affect the subject's health or the study parameters.

          -  History of or presence of any corneal pathology or disease

          -  Presence of an active ocular infection (bacterial, viral or fungal), or positive
             history of ocular herpetic infection.

          -  History of severe dry eye syndrome.

          -  History or evidence of previous ocular surgery in the operative eye.

          -  History of any significant illness that could be expected to interfere with the study
             parameters.

          -  Use of disallowed therapies (systemic or topical):

               -  Fluoroquinolone anti-infective agents (systemic or topical) within 2 weeks of
                  Visit 1 or anytime after Visit 1 for the duration of the study;

               -  Topical ophthalmic preparations (including tear substitutes and rewetting drops),
                  within 1 week of Visit 1 or anytime after Visit 1 for the duration of the study
                  (other than the study medication as restricted above), with the exception of
                  non-steroidal topical ophthalmic drops

          -  Use of contact lenses in the 2 weeks prior to the study and for the duration of the
             study.

          -  Received an experimental drug or used an experimental medical device within 30 days
             before the planned start of treatment.

          -  Pregnant or breast-feeding.

          -  Any condition that, in the opinion of the investigator, would compromise the
             well-being of the subject or the study.

          -  Employees of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bucci Laser Vision &amp; Ambulatory Surgery Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Brian Schwam, MD</name_title>
    <organization>VISTAKON Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Aqueous humor penetration by anti-infectives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 29, 2009</submitted>
    <returned>December 1, 2009</returned>
    <submitted>June 17, 2010</submitted>
    <returned>July 13, 2010</returned>
    <submitted>November 7, 2011</submitted>
    <returned>December 7, 2011</returned>
    <submitted>April 17, 2012</submitted>
    <returned>May 15, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

